Lung Microbiome and Pulmonary Inflammation/Immunity in HIV Infection

HIV 感染中的肺部微生物组和肺部炎症/免疫

• 批准号: 8119577
• 负责人: Homer L Twigg
• 金额: $ 74.41万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-23 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8119577
• 关键词: Academic Medical Centers; Address; Affect; Alveolar; Alveolar Macrophages; Alveolus; Anti-Retroviral Agents; Antibodies; Antigens; Arizona; Automobile Driving; Bacteria; Bioinformatics; Bronchoalveolar Lavage; CD4 Lymphocyte Count; Chronic; Chronic Obstructive Airway Disease; Clinical; Collaborations; Collection; Data; Data Analyses; Defense Mechanisms; Disease; Environment; Future; Gene Pool; Genome; Goals; HIV; Health; Highly Active Antiretroviral Therapy; Homeostasis; Immune; Immunity; Immunoglobulins; Immunologic Deficiency Syndromes; Immunologics; Indiana; Infection; Inflammation; Inflammatory; Inflammatory Response; Institution; Instruction; Interferon Type II; Irrigation; Laboratories; Lead; Liquid substance; Longitudinal Studies; Lower respiratory tract structure; Lung; Lymphocyte; Measures; Metagenomics; Modeling; Molecular; National Heart, Lung, and Blood Institute; Opportunistic Infections; Organism; Oropharyngeal; Paint; Participant; Patients; Phenotype; Physicians; Pneumonia; Predisposition; Prevalence; Procedures; Process; Pulmonary Hypertension; Qualifying; Recording of previous events; Research Personnel; Respiratory System; Respiratory tract structure; Ribosomal RNA; Risk; Saliva; Sampling; Scientist; Secure; Shotgun Sequencing; Shotguns; Smoking; Smoking Status; Specimen; Syndrome; T-Cell Activation; T-Lymphocyte; Techniques; Trees; Universities; Upper respiratory tract; Viral Antigens; Viral Load result; Virus Diseases; Washington; antiretroviral therapy; chemokine; cofactor; cohort; cost; cytokine; data management; improved; macrophage; microbiome; microorganism; pathogen; premature; prospective; reconstitution; respiratory; volunteer

DESCRIPTION (provided by applicant): The lung compartment in Human Immunodeficiency Virus (HIV) infection is characterized by chronic inflammation and severe immunologic derangements. While some of the inflammatory changes may be due to chronic stimulation by HIV in the lung, correlation between these changes and the lung viral load is poor. Thus other factors are likely driving the chronic inflammatory state in the lung. Given the known immunodeficiency in these patients, colonization of the respiratory tract with new or increased numbers of infectious pathogens is highly likely and easily could be contributing to chronic inflammation. Thus we hypothesize that the lung inflammatory and immunologic environment in HIV-infected subjects is directly related to the host microbiome rather than the pulmonary HIV burden, that the immunodeficiency seen leads to a more diverse pulmonary microbiome compared to uninfected subjects, and that highly active antiretroviral therapy (HAART) returns the pulmonary microbiome towards normal. We will make use of a large existing cohort of bronchoalvoelar lavage samples to begin exploring lung microbiomes in normal volunteers and HIV-infected subjects and correlate these with measures of local pulmonary inflammation. These cohorts include HIV-infected subjects with COPD and those studied prior to starting antiretroviral and followed longitudinally for 6-12 months. We will also prospectively study the microbiome along the entire respiratory tract from the oropharynx to the alveoli to determine if what is found in the upper tract can predict lower respiratory microbiomes. To accomplish our goals we propose the following Specific Aims. (1) To compare the respiratory microbiome between HIV-infected subjects and normal volunteers; (2) To directly correlate the relationship between the respiratory microbiome and the pulmonary inflammatory milieu in HIV-infected subjects and normal volunteers; (3) To determine if highly active antiretroviral therapy alters the pulmonary microbiome and local inflammatory response; and (4) To compare the respiratory microbiome in HIV-infected subjects and normal volunteers from the oropharynx to the alveoli. In depth analysis will start with 16s and 18s rRNA sequencing to paint a broad picture of the microorganisms present in the lung. Detailed metagenomic shotgun sequencing will be performed on prospectively identified species to characterize significant gene pools which may directly impact the pulmonary immunologic and inflammatory milieu These studies will greatly enhance our understanding of the lung environment in both health and disease and lead to potential new models defining pulmonary homeostasis.

描述（由申请人提供）：人类免疫缺陷病毒（HIV）感染的肺室的特征是慢性炎症和严重的免疫紊乱。虽然一些炎症变化可能是由于肺部受到艾滋病毒的慢性刺激造成的，但这些变化与肺部病毒载量之间的相关性很差。因此，其他因素可能导致肺部慢性炎症状态。鉴于这些患者已知的免疫缺陷，新的或数量增加的传染性病原体在呼吸道定植很可能并且很容易导致慢性炎症。因此，我们假设 HIV 感染者的肺部炎症和免疫环境与宿主微生物组直接相关，而不是与肺部 HIV 负担相关，与未感染者相比，免疫缺陷导致肺部微生物组更加多样化，并且高活性抗逆转录病毒药物治疗（HAART）使肺部微生物组恢复正常。我们将利用大量现有的支气管肺泡灌洗样本来开始探索正常志愿者和艾滋病毒感染者的肺部微生物群，并将这些样本与局部肺部炎症的测量结果相关联。这些队列包括患有 COPD 的 HIV 感染受试者以及在开始抗逆转录病毒治疗之前进行研究并纵向随访 6-12 个月的受试者。我们还将前瞻性地研究从口咽到肺泡的整个呼吸道的微生物组，以确定上呼吸道中的发现是否可以预测下呼吸道微生物组。为了实现我们的目标，我们提出以下具体目标。 （1）比较HIV感染者与正常志愿者的呼吸道微生物组； (2) 直接关联 HIV 感染者和正常志愿者的呼吸道微生物群与肺部炎症环境之间的关系； (3) 确定高效抗逆转录病毒治疗是否会改变肺部微生物组和局部炎症反应； (4) 比较 HIV 感染者和正常志愿者从口咽到肺泡的呼吸道微生物组。深入分析将从 16s 和 18s rRNA 测序开始，以描绘肺部存在的微生物的概况。将对前瞻性鉴定的物种进行详细的宏基因组鸟枪法测序，以表征可能直接影响肺部免疫和炎症环境的重要基因库。这些研究将极大地增强我们对健康和疾病中肺部环境的理解，并产生定义肺部的潜在新模型。体内平衡。